Stereotactic radiosurgery for recurrent ependymoma

Scott L. Stafford, Bruce E. Pollock, Robert L. Foote, Deborah A. Gorman, Diana F. Nelson, Paula J. Schomberg

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

BACKGROUND. Patients with recurrent intracranial ependymomas were evaluated to assess local control, overall survival, and complications from stereotactic radiosurgery (SRS). METHODS. Twelve patients (with a total of 17 tumors) with recurrent ependymoma underwent SRS. Local failure was defined as tumor progression within the prescription isodose volume, and marginal failure was defined as tumor progression adjacent to the SRS prescription isodose volume. Tumor progression away from the prescription volume was considered distant failure. Eleven of the 12 patients had undergone previous resection and external beam radiation therapy (46-56 Grays [Gy]; median, 54 Gy) before radiosurgery, and 1 patient had failure after complete resection alone. Age at SRS ranged from 5-56 years (median, 29 years). Three patients were female. The marginal tumor dose was 12-24 Gy (median, 18 Gy). One to 14 isocenters (median, 4 isocenters) were utilized to irradiate volumes of 0.3- 15.5 cm3 (median, 3.2 cm3). RESULTS. The duration of follow-up ranged from 2.5-60 months (median, 22.5 months). The median overall survival after SRS was 3.4 years (range, 1.4-5 years). In-field local control was achieved in 14 of the 17 tumor sites and estimated 3-year local control was 68%. There were two in-field failures and one marginal failure. Distant failure occurred in two patients. Two patients developed treatment-related complications after SRS. CONCLUSIONS. SRS provides good local tumor control for patients with recurrent intracranial ependymoma and may have a favorable impact on survival. SRS should be evaluated more extensively in the initial treatment of patients with ependymoma to minimize local failure after surgical management. (C) 2000 American Cancer Society.

Original languageEnglish (US)
Pages (from-to)870-875
Number of pages6
JournalCancer
Volume88
Issue number4
DOIs
StatePublished - Feb 15 2000

Fingerprint

Ependymoma
Radiosurgery
Neoplasms
Prescriptions
Survival
Radiotherapy

Keywords

  • Complications
  • Ependymoma
  • Local control
  • Stereotactic radiosurgery
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Stafford, S. L., Pollock, B. E., Foote, R. L., Gorman, D. A., Nelson, D. F., & Schomberg, P. J. (2000). Stereotactic radiosurgery for recurrent ependymoma. Cancer, 88(4), 870-875. https://doi.org/10.1002/(SICI)1097-0142(20000215)88:4<870::AID-CNCR18>3.0.CO;2-I

Stereotactic radiosurgery for recurrent ependymoma. / Stafford, Scott L.; Pollock, Bruce E.; Foote, Robert L.; Gorman, Deborah A.; Nelson, Diana F.; Schomberg, Paula J.

In: Cancer, Vol. 88, No. 4, 15.02.2000, p. 870-875.

Research output: Contribution to journalArticle

Stafford, SL, Pollock, BE, Foote, RL, Gorman, DA, Nelson, DF & Schomberg, PJ 2000, 'Stereotactic radiosurgery for recurrent ependymoma', Cancer, vol. 88, no. 4, pp. 870-875. https://doi.org/10.1002/(SICI)1097-0142(20000215)88:4<870::AID-CNCR18>3.0.CO;2-I
Stafford SL, Pollock BE, Foote RL, Gorman DA, Nelson DF, Schomberg PJ. Stereotactic radiosurgery for recurrent ependymoma. Cancer. 2000 Feb 15;88(4):870-875. https://doi.org/10.1002/(SICI)1097-0142(20000215)88:4<870::AID-CNCR18>3.0.CO;2-I
Stafford, Scott L. ; Pollock, Bruce E. ; Foote, Robert L. ; Gorman, Deborah A. ; Nelson, Diana F. ; Schomberg, Paula J. / Stereotactic radiosurgery for recurrent ependymoma. In: Cancer. 2000 ; Vol. 88, No. 4. pp. 870-875.
@article{55069977eb3b4f1ea13f870c6923370f,
title = "Stereotactic radiosurgery for recurrent ependymoma",
abstract = "BACKGROUND. Patients with recurrent intracranial ependymomas were evaluated to assess local control, overall survival, and complications from stereotactic radiosurgery (SRS). METHODS. Twelve patients (with a total of 17 tumors) with recurrent ependymoma underwent SRS. Local failure was defined as tumor progression within the prescription isodose volume, and marginal failure was defined as tumor progression adjacent to the SRS prescription isodose volume. Tumor progression away from the prescription volume was considered distant failure. Eleven of the 12 patients had undergone previous resection and external beam radiation therapy (46-56 Grays [Gy]; median, 54 Gy) before radiosurgery, and 1 patient had failure after complete resection alone. Age at SRS ranged from 5-56 years (median, 29 years). Three patients were female. The marginal tumor dose was 12-24 Gy (median, 18 Gy). One to 14 isocenters (median, 4 isocenters) were utilized to irradiate volumes of 0.3- 15.5 cm3 (median, 3.2 cm3). RESULTS. The duration of follow-up ranged from 2.5-60 months (median, 22.5 months). The median overall survival after SRS was 3.4 years (range, 1.4-5 years). In-field local control was achieved in 14 of the 17 tumor sites and estimated 3-year local control was 68{\%}. There were two in-field failures and one marginal failure. Distant failure occurred in two patients. Two patients developed treatment-related complications after SRS. CONCLUSIONS. SRS provides good local tumor control for patients with recurrent intracranial ependymoma and may have a favorable impact on survival. SRS should be evaluated more extensively in the initial treatment of patients with ependymoma to minimize local failure after surgical management. (C) 2000 American Cancer Society.",
keywords = "Complications, Ependymoma, Local control, Stereotactic radiosurgery, Survival",
author = "Stafford, {Scott L.} and Pollock, {Bruce E.} and Foote, {Robert L.} and Gorman, {Deborah A.} and Nelson, {Diana F.} and Schomberg, {Paula J.}",
year = "2000",
month = "2",
day = "15",
doi = "10.1002/(SICI)1097-0142(20000215)88:4<870::AID-CNCR18>3.0.CO;2-I",
language = "English (US)",
volume = "88",
pages = "870--875",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Stereotactic radiosurgery for recurrent ependymoma

AU - Stafford, Scott L.

AU - Pollock, Bruce E.

AU - Foote, Robert L.

AU - Gorman, Deborah A.

AU - Nelson, Diana F.

AU - Schomberg, Paula J.

PY - 2000/2/15

Y1 - 2000/2/15

N2 - BACKGROUND. Patients with recurrent intracranial ependymomas were evaluated to assess local control, overall survival, and complications from stereotactic radiosurgery (SRS). METHODS. Twelve patients (with a total of 17 tumors) with recurrent ependymoma underwent SRS. Local failure was defined as tumor progression within the prescription isodose volume, and marginal failure was defined as tumor progression adjacent to the SRS prescription isodose volume. Tumor progression away from the prescription volume was considered distant failure. Eleven of the 12 patients had undergone previous resection and external beam radiation therapy (46-56 Grays [Gy]; median, 54 Gy) before radiosurgery, and 1 patient had failure after complete resection alone. Age at SRS ranged from 5-56 years (median, 29 years). Three patients were female. The marginal tumor dose was 12-24 Gy (median, 18 Gy). One to 14 isocenters (median, 4 isocenters) were utilized to irradiate volumes of 0.3- 15.5 cm3 (median, 3.2 cm3). RESULTS. The duration of follow-up ranged from 2.5-60 months (median, 22.5 months). The median overall survival after SRS was 3.4 years (range, 1.4-5 years). In-field local control was achieved in 14 of the 17 tumor sites and estimated 3-year local control was 68%. There were two in-field failures and one marginal failure. Distant failure occurred in two patients. Two patients developed treatment-related complications after SRS. CONCLUSIONS. SRS provides good local tumor control for patients with recurrent intracranial ependymoma and may have a favorable impact on survival. SRS should be evaluated more extensively in the initial treatment of patients with ependymoma to minimize local failure after surgical management. (C) 2000 American Cancer Society.

AB - BACKGROUND. Patients with recurrent intracranial ependymomas were evaluated to assess local control, overall survival, and complications from stereotactic radiosurgery (SRS). METHODS. Twelve patients (with a total of 17 tumors) with recurrent ependymoma underwent SRS. Local failure was defined as tumor progression within the prescription isodose volume, and marginal failure was defined as tumor progression adjacent to the SRS prescription isodose volume. Tumor progression away from the prescription volume was considered distant failure. Eleven of the 12 patients had undergone previous resection and external beam radiation therapy (46-56 Grays [Gy]; median, 54 Gy) before radiosurgery, and 1 patient had failure after complete resection alone. Age at SRS ranged from 5-56 years (median, 29 years). Three patients were female. The marginal tumor dose was 12-24 Gy (median, 18 Gy). One to 14 isocenters (median, 4 isocenters) were utilized to irradiate volumes of 0.3- 15.5 cm3 (median, 3.2 cm3). RESULTS. The duration of follow-up ranged from 2.5-60 months (median, 22.5 months). The median overall survival after SRS was 3.4 years (range, 1.4-5 years). In-field local control was achieved in 14 of the 17 tumor sites and estimated 3-year local control was 68%. There were two in-field failures and one marginal failure. Distant failure occurred in two patients. Two patients developed treatment-related complications after SRS. CONCLUSIONS. SRS provides good local tumor control for patients with recurrent intracranial ependymoma and may have a favorable impact on survival. SRS should be evaluated more extensively in the initial treatment of patients with ependymoma to minimize local failure after surgical management. (C) 2000 American Cancer Society.

KW - Complications

KW - Ependymoma

KW - Local control

KW - Stereotactic radiosurgery

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0034651871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034651871&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(20000215)88:4<870::AID-CNCR18>3.0.CO;2-I

DO - 10.1002/(SICI)1097-0142(20000215)88:4<870::AID-CNCR18>3.0.CO;2-I

M3 - Article

C2 - 10679657

AN - SCOPUS:0034651871

VL - 88

SP - 870

EP - 875

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -